24 research outputs found
Selection of the participants for the long-term evaluation analyses in the REDIA-prev1 cohort study.
<p>(Reunion Island, 2001–2011).</p
Reported symptoms and medical consumption.
<p>CHIK+, persons with a history of CHIKV infection confirmed by serology (n = 199); CHIK–, persons confirmed as seronegative for CHIKV (n = 199); RR, relative risks; CI, confidence interval.</p>*<p>RR, relative risks controlling for stratification criteria.</p>†<p>Exact Mac Nemar test.</p
Characteristics of the study population (199 matched pairs).
<p>Characteristics of the study population (199 matched pairs).</p
Maternal glycemic levels during pregnancy (mmol/l) related to offspring BMI (kg/m<sup>2</sup>) at 5–7 years by sex in group exposed to gestational diabetes mellitus.
<p>Maternal glycemic levels during pregnancy (mmol/l) related to offspring BMI (kg/m<sup>2</sup>) at 5–7 years by sex in group exposed to gestational diabetes mellitus.</p
Percentage of patients (n = 199) fully recovered, shown by age group.
<p>The long dash followed by the short dash represents patients aged under 30; the dash represents patients aged 30 to 59 and the solid line represents those aged 60 and over. Recovery is fast in young subjects.</p
Estimating Chikungunya prevalence in La RĂ©union Island outbreak by serosurveys: Two methods for two critical times of the epidemic-1
On-based SEROCHIK survey (right scale). For the serosurvey, both self-reports (all subjects who have declared that they have been infected, without taking into account serology results) and confirmed self-reports (with a positive serology) are noted. We refer to the date of first clinical signs declared by the subjects during the survey conducted between August 172006 and October 202006. "Suspected cases" are defined as cases with a sudden onset of fever with temperature > 38.5°C and incapacitating arthralgia.<p><b>Copyright information:</b></p><p>Taken from "Estimating Chikungunya prevalence in La Réunion Island outbreak by serosurveys: Two methods for two critical times of the epidemic"</p><p>http://www.biomedcentral.com/1471-2334/8/99</p><p>BMC Infectious Diseases 2008;8():99-99.</p><p>Published online 28 Jul 2008</p><p>PMCID:PMC2528011.</p><p></p
Estimating Chikungunya prevalence in La RĂ©union Island outbreak by serosurveys: Two methods for two critical times of the epidemic-0
On-based SEROCHIK survey (right scale). For the serosurvey, both self-reports (all subjects who have declared that they have been infected, without taking into account serology results) and confirmed self-reports (with a positive serology) are noted. We refer to the date of first clinical signs declared by the subjects during the survey conducted between August 172006 and October 202006. "Suspected cases" are defined as cases with a sudden onset of fever with temperature > 38.5°C and incapacitating arthralgia.<p><b>Copyright information:</b></p><p>Taken from "Estimating Chikungunya prevalence in La Réunion Island outbreak by serosurveys: Two methods for two critical times of the epidemic"</p><p>http://www.biomedcentral.com/1471-2334/8/99</p><p>BMC Infectious Diseases 2008;8():99-99.</p><p>Published online 28 Jul 2008</p><p>PMCID:PMC2528011.</p><p></p
Selection of infants for the OBEGEST cohort study (South Reunion Island, 2001–2010).
<p>GDM: gestational diabetes mellitus. GHSR: Groupe Hospitalier Sud-RĂ©union.</p
Gestational diabetes mellitus exposure and co-factors associated with offspring overweight (BMI ≥ IOTF-25) at 5–7 years by sex.
<p>Gestational diabetes mellitus exposure and co-factors associated with offspring overweight (BMI ≥ IOTF-25) at 5–7 years by sex.</p
Quality of life assessment by the SF-12 of subjects with a history of Chikungunya virus infection compared with uninfected subjects.
<p>CHIK+, persons with a history of CHIKV infection confirmed by serology (n = 162); CHIK–, persons confirmed as seronegative for CHIKV (n = 162).</p>*<p>Wilcoxon's rank test for paired samples.</p>†<p>After Bonferroni correction, the statistical significance was then set at p = 0.01 with a bilateral formulation.</p